My #1 Biotech Stock For November

Tiny Biotech Uses a Radical Method to Combat Alzheimer's

Dear Fellow Investor, The challenge in treating Alzheimer's isn't the lack of drugs. It's that you can't get those drugs to reach the brain. You see, the Blood-Brain-Barrier stops 100% of large-molecule drugs from getting to the brain. Small-molecule drugs only fare slightly better. 98% can't make it past the Blood-Brain-Barrier. Nature does this in order to protect the brain. So the question is... How do we ever cure Alzheimer's when our drugs can't even reach the brain? On October 29, 2013, a Jeff Bezos-backed biotech had a radical idea: to employ a "drug smuggler" to help cross the blood-brain-barrier. Big Pharma giants Biogen, Genentech and Sanofi were so stunned when it worked, they spent $1 billion for the rights to the treatment. Never before has so much money invested in a single company so quickly. Jim Cramer estimates this breakthrough would create the "Biggest Drug in the World." We think this stock could rise 10,000% – if it's not taken over first. There's just no way Big Pharma would let this company stay independent. Pfizer, Novartis and Johnson & Johnson make billions selling Alzheimer's drugs each year. They have the most to lose. It's too much of a threat to their business. That's why this tiny biotech is my #1 Biotech Stock for November. "The Buck Stops Here"

#FOOTER#

Stockguru LLC 711 SW 24th Ave Boynton, Beach, FL 33435 This email is being sent from Investing Chatter. If you no longer wish to receive Investing Chatter emails, please click to unsubscribe.

DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.